Key result
High adiponectin levels in metabolic syndrome patients were associated with higher PUFA consumption (6.37 vs 6.06) and a higher omega-3/omega-6 ratio (0.16 vs 0.09) compared to low adiponectin.
Why the study?
Adiponectin mediates antidiabetic and cardioprotective effects, and evidence suggests diet affects its concentration, but its association with cardiometabolic factors, anthropometrics, and diet in obese patients needed evaluation.
Is higher adiponectin concentration associated with more favorable cardiometabolic risk factors and dietary patterns in nondiabetic patients with metabolic syndrome?
Cross-Sectional (n=113)
Is higher adiponectin concentration associated with more favorable cardiometabolic risk factors and dietary patterns in nondiabetic patients with metabolic syndrome?
Absolute Event Rate: 6.37% vs 6.06%
Higher dietary intake of polyunsaturated fatty acids and a higher omega-3/omega-6 ratio are associated with higher circulating adiponectin levels and a more favorable cardiometabolic profile in patients with metabolic syndrome.
Higher adiponectin linked to better cardiometabolic profile and PUFA-rich diet in metabolic syndrome; leaves open whether dietary changes raise levels.
Background: Adiponectin is known to mediate antidiabetic and cardioprotective metabolic effects. Current evidence suggests that diet, both its quantity and quality, affects adiponectin concentration. Methods: The purpose of this study was to evaluate the association of adiponectin with cardiometabolic risk factors, anthropometric features, and diet characteristics in obese patients with multiple cardiometabolic risk factors. The group of 113 nondiabetic patients (90 males, mean age: 48 ± 9 years) fulfilling the criteria of metabolic syndrome (IDF, 2005) was divided into 2 subgroups according to median adiponectin concentration calculated for that cohort (6.83 μg/mL)—low-adiponectin (LA) and high-adiponectin (HA) subgroup. Biochemical and anthropometric measurements were recorded and nutrients intake was assessed using 24-hr dietary recall method and diet history questionnaire. Results: No significant differences between LA and HA were noted regarding the anthropometric parameters. However, there were significant differences in biochemical indices, and HA was characterized by a more favorable insulin level, homeostasis model assessment of insulin resistance (HOMA-IR) value, and plasma lipid profile than LA. Both LA and HA subgroups were comparable in terms of energy, protein, carbohydrate, and total fat intake, but there were significant differences between the level of polyunsaturated fatty acids (PUFA) consumption (6.06 ± 1.0 and 6.37 ± 1.1, respectively) and omega-3/omega-6 ratio (as follows: 0.09 ± 0.01 and 0.16 ± 0.04). Conclusions: These results highlight interactions between diet, adiponectin concentration, and biochemical profile. Nondiabetic patients with metabolic syndrome with higher PUFA consumption, including higher omega-3/omega-6 ratio, were characterized by higher circulating adiponectin level and more favorable biochemical profile. Thus, it might be assumed that the protective role of omega-3 fatty acids might be mediated by adiponectin in patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Pałkowska-Goździk et al. (2020) conducted a cross-sectional in Metabolic syndrome (n=113). High adiponectin concentration (≥6.83 μg/mL) vs. Low adiponectin concentration (<6.83 μg/mL) was evaluated on Polyunsaturated fatty acids (PUFA) consumption. High adiponectin levels in metabolic syndrome patients were associated with higher PUFA consumption (6.37 vs 6.06) and a higher omega-3/omega-6 ratio (0.16 vs 0.09) compared to low adiponectin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: